A Phase 4 interventional study of Secukinumab Auto-Injector in Psoriasis, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 49th largest by enrollment, is the only one that started in 2022, is one of 17 in phase 4, and was the 46th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
10 studies in Psoriasis by University of Pennsylvania: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Psoriasis by University of Pennsylvania, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 4, and was the 9th registered.
University of Pennsylvania’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among University of Pennsylvania’s 10 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.
This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. This is a single arm trial - all patients will receive the study drug. We will examine time to response and different methods of defining nail disease response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Secukinumab
Drug: Secukinumab Auto-Injector
300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
Also known as: Cosentyx
Change in NAPSI
Nail Psoriasis Severity Index (NAPSI): NAPSI is the most comprehensive nail assessment used in clinical trials. The fingernail is divided into four quadrants. For each quadrant, 1 point is assigned for a nail matrix abnormality and 1 point for a nail bed abnormality allowing for a total of 8 points per nail. 0-80 total points possible with a higher score corresponding to a worse outcome.
Time frame: 24 Weeks
Change in mNAPSI
modified Nail Psoriasis Severity Index (mNAPSI): A modified version of the primary outcome measure, the mNAPSI includes more features of nail disease. It has previously demonstrated greater correlation with the physician global assessment, assessing the nail as a whole rather than quadrants with improved reliability and responsiveness. 0-130 total points possible with a higher score corresponding to a worse outcome.
Time frame: 24 Weeks
Change in Physician Global Assessment of Nail Disease
Physician Global Assessment of Nail Disease. Scale of 0-100 with higher score corresponding to a worse outcome (0=clear, 100=very severe).
Time frame: 24 Weeks
Change in Patient Global Assessment of Nail Disease
Patient Global Assessment of Nail Disease. Scale of 0-10 with higher score corresponding to a worse outcome (0=excellent, 10=poor).
Time frame: 24 Weeks
Change in PASI
Psoriasis Area Severity Index (PASI): Four assessments for each of four body areas (head, trunk, upper extremities, and lower extremities) are provided. The assessments are erythema, induration, and scale (each assessed as 0-4 using a standardized scale), and the number of palms/percentage of each area is categorized (0 = 0%, 1 = less than 10%, 2 = 10%-29%, 3 = 30%-40%, 4 = 50%-69%, Scale of 0 to 72 with a higher score corresponding to a worse outcome.
Time frame: 24 Weeks
Change in DLQI
Dermatology Life Quality Index (DLQI): There are a total of 10 questions and each question is scored on a four-point Likert scale: Very much = 3 A lot = 2 A little = 1 Not at all = 0 Not relevant = 0 Question unanswered = 0 The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.
Time frame: 24 Weeks
Change in NAPPA
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Patient-reported outcome designed to emphasize quality of life, patient-related needs, and treatment benefit. The NAPPA captures domains such as pain, function, cosmetic, and psychosocial burden. The NAPPA QoL contains 20 questions, each scored on a five-point Likert scale: 0 = not at all 1. = somewhat 2. = moderately 3. = quite a bit 5 = very The score is calculated by adding the score of each question, resulting in a maximum of 100 and a minimum of 0. Higher score indicates greater impact of disease.
Time frame: 24 Weeks
| Milestone | Open Label |
|---|---|
| Started | 16 |
| Completed | 10 |
| Not completed | 6 |
Nail Psoriasis Severity Index (NAPSI): NAPSI is the most comprehensive nail assessment used in clinical trials. The fingernail is divided into four quadrants. For each quadrant, 1 point is assigned for a nail matrix abnormality and 1 point for a nail bed abnormality allowing for a total of 8 points per nail. 0-80 total points possible with a higher score corresponding to a worse outcome.
| score on a scale | Open Label |
|---|---|
| Change in NAPSI | -23.7 ± 14.3 |
modified Nail Psoriasis Severity Index (mNAPSI): A modified version of the primary outcome measure, the mNAPSI includes more features of nail disease. It has previously demonstrated greater correlation with the physician global assessment, assessing the nail as a whole rather than quadrants with improved reliability and responsiveness. 0-130 total points possible with a higher score corresponding to a worse outcome.
| score on a scale | Open Label |
|---|---|
| Change in mNAPSI | -20.2 ± 14.2 |
Physician Global Assessment of Nail Disease. Scale of 0-100 with higher score corresponding to a worse outcome (0=clear, 100=very severe).
| score on a scale | Open Label |
|---|---|
| Change in Physician Global Assessment of Nail Disease | -36.5 ± 11.4 |
Patient Global Assessment of Nail Disease. Scale of 0-10 with higher score corresponding to a worse outcome (0=excellent, 10=poor).
| score on a scale | Open Label |
|---|---|
| Change in Patient Global Assessment of Nail Disease | -2.2 ± 3.1 |
Psoriasis Area Severity Index (PASI): Four assessments for each of four body areas (head, trunk, upper extremities, and lower extremities) are provided. The assessments are erythema, induration, and scale (each assessed as 0-4 using a standardized scale), and the number of palms/percentage of each area is categorized (0 = 0%, 1 = less than 10%, 2 = 10%-29%, 3 = 30%-40%, 4 = 50%-69%, Scale of 0 to 72 with a higher score corresponding to a worse outcome.
| score on a scale | Open Label |
|---|---|
| Change in PASI | -3.1 ± 2.7 |
Dermatology Life Quality Index (DLQI): There are a total of 10 questions and each question is scored on a four-point Likert scale: Very much = 3 A lot = 2 A little = 1 Not at all = 0 Not relevant = 0 Question unanswered = 0 The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.
| score on a scale | Open Label |
|---|---|
| Change in DLQI | -8.1 ± 7.1 |
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Patient-reported outcome designed to emphasize quality of life, patient-related needs, and treatment benefit. The NAPPA captures domains such as pain, function, cosmetic, and psychosocial burden. The NAPPA QoL contains 20 questions, each scored on a five-point Likert scale: 0 = not at all 1. = somewhat 2. = moderately 3. = quite a bit 5 = very The score is calculated by adding the score of each question, resulting in a maximum of 100 and a minimum of 0. Higher score indicates greater impact of disease.
| score on a scale | Open Label |
|---|---|
| Change in NAPPA | -20.7 ± 17.9 |
Collected over Baseline to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Age, Continuous(years) | Open Label |
|---|---|
| Mean | 48.4 ± 13 |
| Sex: Female, Male(Participants) | Open Label |
|---|---|
| Female | 5 |
| Male | 5 |
| Race (NIH/OMB)(Participants) | Open Label |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| PASI(score on a scale) | Open Label |
|---|---|
| Mean | 3.9 ± 2.9 |
| NAPSI(score on a scale) | Open Label |
|---|---|
| Mean | 33.9 ± 16.3 |
| mNAPSI(score on a scale) | Open Label |
|---|---|
| Mean | 25.8 ± 16.5 |
| Physician Nail Global Assessment(score on a scale) | Open Label |
|---|---|
| Mean | 56 ± 13.6 |
| Patient Nail Global Assessment(score on a scale) | Open Label |
|---|---|
| Mean | 4.8 ± 2.4 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2022 to primary completion in May 2025, 39 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion.
Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 39 months is above that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab